Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis
Prognosis Value of the Neuronal Damage Detected by Positrons Emission Tomography (PET) With 11C-Flumazenil in Early Multiple Sclerosis.
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- PET with 11C-Flumazenil
What it measured
Main measures
neuronal imaging
2 years
Disability progressionBrain volume loss
Who could take part
Relapsing and progressive · 18 to 55
Show the full criteria
Inclusion criteria
Four groups of subjects will be included: * patients with a RRMS evolving since less than 5 years (revised Mc Donald criteria, n=20); * patients with a RRMS evolving since more than 5 years and less than 10 years (n=20); * patients with a primary progressive MS (PPMS) evolving since less than 10 years (n=20); * Healthy volunteers matched for age and sex (2/3 matched with RRMS patients; 1/3 matched with PPMS patients).
Exclusion criteria
* Lack of social insurance * Pregnancy * Age > 55 * Therapy with benzodiazepine
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
In this study the investigators will use PET and 11C-Flumazenil to visualize and quantify neuronal injury in the cortex and the deep gray matter of Multiple Sclerosis patients at an early stage. The investigators will follow up patients to determine the prognostic value of this neuronal injury.
Papers
Loading reviews and guidelines…
History
Started
Jun 2013
Main results due
Jun 2019
Finished
Jun 2019